Skip to main content

Table 2 Patient characteristics

From: Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial

   Level 1 (n = 3) n (%) Level 2 (n = 3) n (%) Level 3 (n = 6) n (%) Total (n = 12) n (%)
Age Median 62 67 64.5 64.5
Range 47–68 62–79 47–80 47–80
PS 0 3 3 5 11 (91.7)
1 0 0 1 1 (8.3)
2 0 0 0 0 (0)
TNM staging Stage II 1 1 1 3 (25.0)
Stage IIIA 0 0 3 3 (25.0)
Stage IIIB 1 1 0 2 (16.7)
Stage IVA 0 0 0 0 (0)
Stage IVB 1 1 2 4 (33.3)
Virus infection HBV 2 2 3 7 (58.3)
HCV 1 1 1 3 (25.0)
Non-B, non-C 0 0 2 2 (16.7)
Child–Pugh score 5 3 2 2 7 (58.3)
6 0 1 2 3 (25.0)
7 0 0 2 2 (16.7)
Extrahepatic metastasis No 2 2 4 8 (66.7)
Yes 1 1 2 4 (33.3)
History of sorafenib No 2 2 3 7 (58)
Yes 1 1 2 5 (42)
History of TACE No 0 0 1 1 (8.3)
  Yes 3 3 5 11 (91.7)
  1. PS, Eastern Cooperative Oncology Group performance status; TNM, tumor node metastasis according to American Joint Committee on Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transcatheter arterial chemoembolization.